Document Type
Article Presentation
Original Publication Date
2022
Date of Submission
April 2022
Abstract
Triple negative breast cancer is an aggressive subtype of breast cancer characterized by its lack of estrogen and progesterone receptors, as well as no or low levels of human epidermal growth factor 2. Ly et al. found that the ganglioside GD2 is highly expressed in a stem cell-like population of triple negative breast cancer tumor and helps with cell adhesion and migration. Using a xenograft model, the researchers determined that targeting this cell population with dinutuximab (anti-GD2 antibody) could prevent tumor growth and metastasis.
Rights
© The Author(s)
